Wealthfront Advisers LLC Acquires 17,793 Shares of Humana Inc. (NYSE:HUM)

Wealthfront Advisers LLC grew its holdings in shares of Humana Inc. (NYSE:HUM) by 130.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 31,408 shares of the insurance provider’s stock after buying an additional 17,793 shares during the period. Wealthfront Advisers LLC’s holdings in Humana were worth $7,969,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Pzena Investment Management LLC raised its position in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. FMR LLC raised its position in shares of Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Humana by 55.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after purchasing an additional 214,535 shares during the last quarter. Retirement Systems of Alabama raised its position in shares of Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after purchasing an additional 192,801 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new position in shares of Humana in the 3rd quarter worth about $50,102,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE HUM opened at $249.32 on Thursday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The stock has a market cap of $30.08 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.05 and a beta of 0.57. The company’s 50 day moving average is $271.59 and its two-hundred day moving average is $281.42. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.42%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is 35.58%.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Truist Financial lifted their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Barclays lifted their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Twenty analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.